Form 4: Boundless Bio Executive David Hinkle Reports Stock Option Grant

David Hinkle, SVP of Finance and Controller at Boundless Bio, reports the acquisition of stock options.

Summary

• David Hinkle, SVP of Finance and Controller Principal Accounting Officer at Boundless Bio, Inc., filed a Form 4 on January 23, 2025, reporting a transaction.
• On January 22, 2025, Hinkle acquired 65,000 stock options with an exercise price of $2.57.
• The options vest in 48 substantially equal monthly installments beginning on February 1, 2025, and expire on January 21, 2035.
• Following the transaction, Hinkle directly owns 65,000 shares of Common Stock.

Sentiment

Score: 6

Explanation: The document is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to a key executive like David Hinkle can be seen as a positive incentive for him to contribute to the company's success.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of executive compensation in the biotechnology industry.
• The vesting schedule of 48 months is also typical.
• Comparing the size of the grant to similar companies would require further analysis of Boundless Bio's compensation structure and market capitalization.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.

Key Dates